Press Room

2016 AIChE Annual Meeting

Start
Sunday, November 13, 2016 - 00:00
End
Friday, November 18, 2016 - 00:00
Location: San Francisco, United States
Cocrystals amorphous solid dispersions | Hovione

HOVIONE PRESENTATIONS

1. Multi-Scale Modeling in Pharmaceutical Drug Substance Manufacturing

José L.C. Santos, Rui C. Silva and Filipe A.P. Ataíde

Date: Monday, Nov 14

Presentation Time: 12:30 PM

Location: Continental 5 (Hilton San Francisco Union Square)

2. Evaporation of Binary Mixtures and Shell Formation in Spray Dried Droplets

Pedro Valente, Íris Duarte, Tiago Porfirio, Xu Liu, Feng Zhang and Márcio Temtem (in collaboration with University of Texas)

Session: Tools for Accelerating Pharma Development and Innovations in Biopharmaceutical Discovery, Development, and Manufacturing 

Date: Tuesday, Nov 15

Presentation Time: 1:58 PM - 2:20 PM 

Location: Continental 5 (Hilton San Francisco Union Square)

3. Evaluating Mixing Performance in a Stirred Tank Reactor with Different Impeller Geometries and Reactor Size By CFD

Rui C. Silva
, Filipe A.P. Ataíde and José L.C. Santos

Date: Wednesday, Nov 16

Presentation Time: 8:30 AM

Location: Union Square 1 & 2 (Hilton San Francisco Union Square)

4. Scale-up of Reaction and Crystallization Steps of a Commercial Manufacturing Process in a Multi-Purpose Plant Using Mechanistic Modeling 

Filipe A.P. Ataíde, Rui C. Silva and José L.C. Santos

Date: Thursday, Nov 17

Presentation Time: 10:15 AM

Location: Continental 4 (Hilton San Francisco Union Square)

5. Secondary Drying Scale-up Methodology: Eliminating a bottleneck with a Lean Development Approach

Tiago Porfirio, Pedro Valente, Ines Matos, Jorge Moreira, João Vicente, Márcio Temtem and Viriato Semião

Session: Quality By Design in Drug Product Formulation, Design, & Process Development I 

Date: Thursday, Nov 17

Presentation Time: 1:08 PM - 1:27 PM 

Location: Continental 4 (Hilton San Francisco Union Square)

 

HOVIONE POSTERS at POSTER SESSION

Date: Monday, November 14, 2016

Session Time: 3:15 PM - 5:45 PM

Location: Grand Ballroom B (Hilton San Francisco Union Square)

 

1. Modelling Approaches to Spray Drying Process Development, Scale-up and Troubleshooting

Pedro Valente, Íris Duarte, Filipe  Neves and Márcio Temtem

2. Predicting the In Vivo Performance of Amorphous Solid Dispersions Based on Molecular Descriptors and Statistical Analysis

Íris Duarte, João Henriques, João F. Pinto, Márcio Temtem

 

Contact us if you would like to schedule a meeting or to find more about the Hovione presentations at 2016 AIChE Annual Meeting.

Schedule a meeting button | Hovione

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026